• 1. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 2. An antimonate pyrochlore (H1.23Sr0.45SbO3.48) for photocatalytic oxidation of benzene: effective oxygen usage and excellent activity?
  Jing Chen,Yu Shao,Danzhen Li J. Mater. Chem. A, 2017,5, 937-941
• 3. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 4. An atomically efficient, highly stable and redox active Ce0.5Tb0.5Ox (3% mol.)/MgO catalyst for total oxidation of methane?
  Juan J. Sánchez,Miguel López-Haro,Juan C. Hernández-Garrido,Ginesa Blanco,Miguel A. Cauqui,José M. Rodríguez-Izquierdo,José A. Pérez-Omil,José J. Calvino,María P. Yeste J. Mater. Chem. A, 2019,7, 8993-9003
• 5. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Spironolactones and derivatives
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Steroid lactones Spironolactones and derivatives

Des-methylformate Eplerenone and CAS No. 50394-27-9: A Comprehensive Overview

Des-methylformate Eplerenone, a derivative of the well-known cardiovascular drug Eplerenone, represents a significant area of interest in the field of pharmaceutical chemistry and medicine. The compound is identified by the CAS number 50394-27-9, which serves as a unique identifier for chemical substances. This introduction aims to provide a detailed exploration of Des-methylformate Eplerenone, its chemical properties, pharmacological significance, and the latest research findings that underscore its importance in modern therapeutic strategies.

The chemical structure of Des-methylformate Eplerenone is closely related to that of Eplerenone, which is a selective aldosterone antagonist used primarily for the treatment of hypertension and heart failure. The presence of the Des-methylformate moiety suggests modifications that may influence its pharmacokinetic and pharmacodynamic profiles. Understanding these modifications is crucial for developing new therapeutic agents with improved efficacy and safety profiles.

In recent years, there has been growing interest in the development of novel derivatives of existing drugs to enhance their therapeutic potential. Des-methylformate Eplerenone falls into this category, as it represents a structural modification that could lead to new insights into aldosterone receptor antagonism. The compound's ability to interact with the aldosterone receptor may offer benefits beyond those provided by conventional treatments, making it a promising candidate for further investigation.

One of the key areas of research involving Des-methylformate Eplerenone has been its potential role in managing cardiovascular diseases. Studies have indicated that selective aldosterone antagonists like Eplerenone can significantly reduce blood pressure and mitigate the risk of cardiovascular complications. The modifications introduced in Des-methylformate Eplerenone may enhance its binding affinity or prolong its duration of action, thereby improving patient outcomes.

The pharmacological activity of Des-methylformate Eplerenone is primarily attributed to its interaction with the mineralocorticoid receptor (MR), which is a critical target in the regulation of sodium and potassium balance, blood pressure, and fluid balance in the body. By blocking aldosterone binding to this receptor, Des-methylformate Eplerenone can help maintain electrolyte balance and reduce blood pressure levels. This mechanism makes it particularly relevant for conditions such as hypertension and heart failure.

Recent preclinical studies have provided valuable insights into the pharmacological properties of Des-methylformate Eplerenone. These studies have focused on evaluating its efficacy, safety, and potential side effects. The results suggest that Des-methylformate Eplerenone may exhibit similar benefits to Eplerenone but with potentially improved pharmacokinetic characteristics. This could translate into more consistent therapeutic effects with fewer side effects for patients.

The synthesis and characterization of Des-methylformate Eplerenone have also been subjects of considerable interest. Advanced synthetic methodologies have been employed to produce this compound with high purity and yield. Techniques such as solid-phase synthesis and chiral resolution have been particularly useful in achieving the desired structural modifications. These advancements in synthetic chemistry are crucial for ensuring that sufficient quantities of Des-methylformate Eplerenone are available for further research and development.

In addition to its therapeutic applications, Des-methylformate Eplerenone has also been explored for its potential role in basic research related to steroid receptor biology. By studying this compound, researchers can gain deeper insights into the mechanisms underlying aldosterone receptor function and develop new strategies for modulating these pathways. Such knowledge could have far-reaching implications for treating not only cardiovascular diseases but also other conditions influenced by aldosterone signaling.

The regulatory landscape for novel pharmaceutical compounds like Des-methylformate Eplerenone is complex and requires careful navigation. Regulatory agencies such as the FDA and EMA have stringent requirements for evaluating the safety and efficacy of new drugs before they can be approved for clinical use. However, the promising results from preclinical studies provide a strong foundation for advancing Des-methylformate Eplerenone through regulatory pathways towards clinical trials.

Future directions in research on Des-methylformate Eplerenone may include exploring its potential in combination therapies with other cardiovascular drugs. Such combinations could offer synergistic effects that enhance treatment outcomes while minimizing side effects. Furthermore, investigating the compound's long-term effects will be essential to ensure its safety profile is well understood before broader clinical application.

The development of novel derivatives like Des-methylformate Eplerenone underscores the dynamic nature of pharmaceutical research and innovation. By building upon established molecular frameworks and introducing strategic modifications, researchers can uncover new therapeutic possibilities that address unmet medical needs. The case of Des-methylformate Eplerenone exemplifies how targeted chemical modifications can lead to significant advancements in drug design and development.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)